Streetbeat News

HLVX

HilleVax, Inc.

https://www.hillevax.com

Industry

Biotechnology

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Open

1.94

Mkt cap

91M

Volume

250K

High

1.94

P/E Ratio

-0.59

52-wk high

20.22

Low

1.83

Div yield

N/A

52-wk low

1.55

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on HilleVax (NASDAQ:HLVX) with a maintained price target of $28.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 12:34 pm

HilleVax (NASDAQ:HLVX) reported Q1 2024 adjusted EPS losses of $(0.97), missing the consensus estimate of $(0.84) by 15.48%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:10 pm

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on HilleVax (NASDAQ:HLVX) and maintained a $28 price target.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:27 am

HilleVax (NASDAQ:HLVX) reported Q4 earnings, beating estimates with an EPS of $-0.78 against an expected $-0.83, a 6.0% beat. However, revenue remained unchanged from the previous year. Following a similar earnings beat last quarter, HLVX's share price increased by 6.0% the next day.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:30 pm

HilleVax reported a Q4 2023 GAAP EPS of $(0.78), surpassing the analyst consensus estimate of $(0.83) by 6.02%.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 8:16 pm

HilleVax and Kangh have entered into an exclusive license agreement for the development and commercialization of a hexavalent VLP norovirus vaccine candidate outside of China. This partnership could potentially enhance HilleVax's product pipeline and market reach, while providing Kangh with licensing revenues and a share in the global market, excluding China.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:13 pm

HC Wainwright & Co. analyst Matthew Caufield has initiated coverage on HilleVax (NASDAQ:HLVX) with a Buy rating and set a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:25 am

Guggenheim analyst Seamus Fernandez has maintained a Buy rating on HilleVax (NASDAQ:HLVX) but reduced the price target from $38 to $34.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 7:02 pm

Stifel analyst Stephen Willey has maintained a Buy rating on HilleVax (NASDAQ:HLVX) but has reduced the price target from $35 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 8:26 pm

HilleVax (NASDAQ:HLVX) reported Q3 losses of $(0.81) per share, beating the analyst consensus estimate of $(0.84) by 3.57 percent. However, this is an 80 percent increase in losses compared to $(0.45) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.